Catalytic RNA molecules, or ribozymes, have generated significant interest as potential therapeutic agents for controlling gene expression. Although ribozymes have been shown to work in vitro and in cellular assays, there are no reports that demonstrate the efficacy of synthetic, stabilized ribozymes delivered in vivo. We are currently utilizing the rabbit model of interleukin 1-induced arthritis to assess the localization, stability, and efficacy of exogenous antistromelysin hammerhead ribozymes. The matrix metalloproteinase stromelysin is believed to be a key mediator in arthritic diseases. It seems likely therefore that inhibiting stromelysin would be a valid therapeutic approach for arthritis. We found that following intraarticular administration ribozymes were taken up by cells in the synovial lining, were stable in the synovium, and reduced synovial interleukin la-induced stromelysin mRNA. This effect was demonstrated with ribozymes containing various chemical modifications that impart nuclease resistance and that recognize several distinct sites on the message. Catalytically inactive ribozymes were ineffective, thus suggesting a cleavage-mediated mechanism of action. These results suggest that ribozymes may be useful in the treatment of arthritic diseases characterized by dysregulation of metalloproteinase expression.
controlling gene expression (4) . Naturally occurring ribozymes come in a variety of structural motifs (5) . Although most ribozymes evolved to cleave their target sequences in cis, ribozymes have also been shown to function in trans (6, 7) . Thus, ribozymes have exceptionally broad potential as therapeutic agents for the selective control of gene expression. Of the naturally occurring ribozymes, the hammerhead (8) is the smallest of the known ribozyme motifs and therefore the most amenable to chemical synthesis. It is also well characterized with respect to kinetic parameters and optimal target sequence, and potential cleavage sites are abundant on most messages.
To develop therapeutic ribozymes, significant research has been devoted to improving catalytic activity, developing nuclease resistance, and optimizing the intracellular delivery of both synthetic and expressed ribozymes (8) (9) (10) (11) . Synthetic ribozymes have shown efficacy in cell culture in reducing the expression of tumor necrosis factor-a (12) , bcr-abl (13) , and MDR-1 (14) . These studies utilized either chemically synthesized chimeric ribozymes with DNA binding arms to increase nuclease resistance or in vitro transcribed ribozymes that are protected in part from degradation by being complexed with cationic lipids. We have used ribozymes that contain novel
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modifications that allow significant catalytic activity while substantially enhancing their nuclease resistance (15) .
There are only a few examples of ribozyme activity in vivo, and these involve expression of the ribozyme as a transgene either in Drosophila (16) or in mice (17, 18) . Demonstration of in vivo efficacy represents an important advance in the development of synthetic ribozymes as therapeutic agents.
The matrix metalloproteinases (MMPs) are a group of enzymes that degrade extracellular matrix components such as the collagens, gelatins, proteoglycans, and fibronectin (19) . Although MMPs play an important role in embryogenesis and normal tissue remodeling (20) , abnormal expression may contribute to such disease processes as atherosclerosis (21) , cancer (22) , and arthritis (23) . Stromelysin (MMP3) may be a key mediator in arthritic diseases. It degrades proteoglycans and a broad spectrum of other matrix components (19) , and it can readily degrade cartilage in vitro (24) . Stromelysin also has the capacity to activate the proenzyme forms of collagenase (25) , and the 72-(26) and 92-kDa (27) gelatinases, thus initiating a proteinase cascade. Unlike normal synovial fibroblasts, those derived from osteoarthritic or rheumatoid synovium produce high levels of stromelysin and collagenase upon stimulation (28) . Most relevant, however, is the marked upregulation of stromelysin and other MMPs seen in articular tissues from patients with osteo-or rheumatoid arthritis (29, 30) . It seems likely therefore that inhibiting stromelysin would be a valid therapeutic approach for arthritis.
In the rabbit, injection of human recombinant interleukin le1 (IL-la) into the knee joint leads to leukocyte accumulation in the joint space, loss of proteoglycan from the articular cartilage, and release of proteoglycan fragments into the synovial fluid (31) . An increase in the levels of the MMPs stromelysin and collagenase in the rabbit articular tissues also occurs after stimulation with IL-1 (32, 33). These attributes make it an appropriate model for assessing the role of proteases involved in the pathophysiology of joint disease. We are using this model to assess the localization, stability, and efficacy of exogenous antistromelysin hammerhead ribozymes. These ribozymes are modified to enhance their resistance to nucleolytic degradation (34) . We found that ribozymes are taken up by cells in the synovial lining after intraarticular administration. The ribozymes demonstrate good stability in the synovium and can significantly reduce the synovial levels of IL-1-induced stromelysin mRNA. Catalytically inactive ribozymes had little effect on stromelysin mRNA levels. This report demonstrates efficacy of an exogenous synthetic ribozyme in vivo.
MATERIALS AND METHODS
Ribozyme Synthesis and Sequences. Ribozymes were synthesized and purified as described by Wincott et al. (35) Unless otherwise indicated, backbone linkages are phosphodiester. These ribozymes are designated U4, U7 NH2, and 3'-iT. In some cases, the ribozymes contained four phosphorothioate linkages at the 5' end (designated U4, U7 NH2, 4 5' P=S, and 3'-iT). An alternative chemistry of ribozyme 1049 was also used in which position U4 was 2'-C-allyl, position U7 was 2'-O-methyl, and five phosphorothioate linkages were included on both the 5' and 3' ends (U4 C-allyl, 5&5 P=S). The catalytic cleavage activity of all of the ribozymes was verified on a complementary short substrate by standard methods; inactive ribozymes did not exhibit any detectable cleavage activity under these conditions (data not shown).
In Vivo Localization and Stability of Ribozymes Delivered Intraarticularly. Male New Zealand White rabbits (3-4 kg) were anesthetized with ketamine.HCl/xylazine and injected intraarticularly with -15 x 106 cpm (corresponding to 30 ng) of 32p internally labeled ribozyme combined with 10 ,g of unlabeled ribozyme in a total vol of 0.5 ml of phosphatebuffered saline (PBS). At various times thereafter, animals were euthanized, the knee joints were lavaged, and synovial tissue was removed, weighed, and either snap frozen for sectioning and autoradiography or placed in Trizol reagent (GIBCO/BRL) for RNA extraction. After initial homogenization of the synovial tissues for RNA extraction, an aliquot was removed to estimate cpm per mg of synovial tissue (assuming that 20% of the synovium was harvested). After extraction of total RNA from the synovial tissue, equal amounts of RNA were run on a denaturing 5% acrylamide gel and the gel was exposed to x-ray film for densitometric quantitation.
In Situ Hybridization. In situ hybridization studies were carried out using full-length antisense RNA probes generated by in vitro transcription of linearized pRC/CMV plasmid (Invitrogen) containing an -1500-bp rabbit stromelysin cDNA (gift of C. Brinckerhoff, Dartmouth Medical School). Samples of synovial tissue were removed, snap frozen in liquid nitrogen, and stored at -80'C. Frozen sections (4-6 jam) were placed on poly(L-lysine)-treated slides and stored at -20°C. Modifications of previously described methods were used (36) .
Efficacy Studies. Rabbits were anesthetized with ketamine HCl/xylazine and injected intraarticularly through the suprapatellar ligament of both knees with various amounts of ribozyme in 0.5 ml of PBS or in PBS alone. Twenty-four hours after ribozyme administration, each rabbit received 25 ng of (36) . After probing with a full-length antisense RNA probe to stromelysin (see above), the blots were stripped and reprobed with a 100-nt complementary RNA probe to 18S rRNA (Ambion, Austin, TX) to normalize for loading and extraction efficiency. After autoradiography, levels of stromelysin and 18S rRNA were quantified on a scanning densitometer and the data were normalized to the 18S values. In some experiments, RNA was analyzed by both Northern blot analysis and RNase protection (P.A.P., unpublished data). The results were essentially the same when assessed by either method.
RESULTS
Delivery of Ribozymes to Rabbit Synovial Tissues. For these studies, ribozyme labeled with 32P at one internal position was administered directly into the intraarticular space. The fate of the labeled ribozyme was assessed 4 and 24 hr postribozyme administration in the first experiment, and 1, 3, and 7 days after administration in the second. The percentage of labeled ribozyme remaining in the synovial tissue remained relatively constant between 4 and 24 hr (Table 1, Exp. 1). In the total RNA fraction, however, there was a 10-fold increase in associated radioactivity during the same time period. § Between 1 and 7 days, there was a 2-fold drop in the total RNA radioactivity and a 4-fold drop in synovial radioactivity ( 24 hr demonstrated that the bulk of the radioactivity was associated with the synovial lining and was intracellular (Fig. 1A) .
The integrity of the labeled ribozyme extracted with the total synovial RNA at the various times is also shown in Fig.  1 . At 4 hr no degradation products could be detected, and by 24 hr the ribozyme remained 80-90% intact (Fig. 1B ). There were no consistent differences in either the amount or the integrity of labeled ribozyme extracted from IL-1-treated and nontreated knees. The substantial increase in labeled ribozyme present at 24 vs. 4 hr noted above was readily apparent. Fig. 1C shows ribozyme integrity at 1, 3, and 7 days. Even after §These results may be explained by recent studies which indicate that fluorescent ribozyme present in synovial cells 4 hr after administration is mostly endosomal, while at 24 hr there is a more diffuse cytoplasmic fluorescence (data not shown). Therefore, although the total amount present in the tissues may have been similar at 4 and 24 hr (as assessed by total tissue homogenates), at 4 hr the endosomal ribozymes may have been lost in the RNA extraction if the endosomes were not disrupted during the homogenization procedure. (Fig. 2) . IL-1 induced a marked but transient increase in the levels of stromelysin mRNA that peaked 6 hr post-IL-1 infusion and returned to near baseline by 24 lysin expression, which followed the same kinetics (data not shown).
Stromelysin mRNA present in IL-1-induced synovial tissue was also visualized by in situ hybridization. Fig. 3A illustrates the high level of stromelysin expression observed in the synovial lining from IL-1-treated joints and its absence in the underlying tissue. An adjacent section of IL-1-treated tissue incubated with the sense RNA probe was completely negative (Fig. 3B ). Fig. 3C shows the much reduced expression observed in control, saline-injected knees. Little or no expression was observed in untreated knees (data not shown).
Reduction in Stromelysin mRNA Levels by Intraarticular
Delivery of Synthetic Ribozymes. Delivery studies (Fig. 1 ) demonstrated that peak intact ribozyme levels were observed in the synovium 24 hr after injection. Therefore, we chose to administer ribozyme 24 hr before IL-1 stimulation for the efficacy studies. The synovial tissue was harvested for RNA analysis 6 hr post-IL-1 infusion, the peak of induced stromelysin mRNA levels (Fig. 2) .
A representative dose-response curve for ribozyme 1049 (U4, U7 NH2, and 3'-iT) demonstrated a significant reduction in stromelysin message at both the 100 and 300 ,ug per knee dose of active ribozyme (Fig. 4) . At a 1.0-mg dose, the efficacy of the active ribozyme was unchanged or slightly reduced from that seen with the 100-,ug dose (data not shown). This ribozyme had been tested on numerous occasions and resulted in an average 60% reduction (ranging from 20% to 80%) in stromelysin message levels compared to the level observed in control, vehicle-treated animals. The inactive ribozyme control retains binding arms identical to the active version but In general, ribozymes that contain mutations that render them inactive were ineffective in reducing stromelysin mRNA levels, thus supporting a cleavage mechanism for ribozyme activity.
These results suggest that ribozymes may be useful in the treatment of arthritic diseases characterized by dysregulation of metalloproteinase expression.
Ribozymes have shown potential as a viable approach for the treatment of malignancies and AIDS. In the area of cancer, ribozymes to several different targets have been developed that are capable of reversing the transformed phenotype and reducing cell proliferation or tumorigenicity (13, 37, 38) . A variety of ribozymes targeting human immunodeficiency virus have also been reported (39) (40) (41) . Thus, a body of literature is emerging that illustrates the therapeutic potential for ribozymes in a broad spectrum of disease conditions.
The initial findings that synthetic DNA oligonucleotides (42) or antisense sequences expressed intracellularly (43) could interfere with gene expression have stimulated considerable research in the area of antisense therapeutics. Poor specificity with DNA oligonucleotides has, however, been a recurrent problem with the antisense strategy (44) (45) (46) . The lack of efficacy observed with inactive ribozyme controls in this study is evidence of a high degree of specificity by ribozymes. In addition, it provides strong support for a cleavage-mediated mechanism of action.
The therapeutic potential of stromelysin ribozymes in the treatment of arthritis remains to be determined. Experiments to evaluate the impact of stromelysin reduction on cartilage proteoglycan levels remain to be done. We do not yet know whether the enzyme levels decrease concordantly with the mRNA or the degree of enzyme reduction necessary to see a therapeutic effect. Because multiple metalloproteinases may be involved in the pathogenesis of arthritis, there may be an advantage in targeting more than one enzyme. In addition, several delivery issues must be addressed. For example, chondrocytes, as well as synoviocytes, produce stromelysin after IL-1 stimulation. We are assessing the relative contribution of these enzyme sources to cartilage proteoglycan loss as well as the ribozyme uptake by these tissues. For chronic conditions such as arthritis, sustained release approaches would be beneficial, and several are under consideration.
